File

Matinas BioPharma Prices $10 Million Registered Direct Offering

Retrieved on: 
Wednesday, April 3, 2024
Form, Prospectus, LNC, File, Sale, Madison Avenue, S-3, Security (finance)

The gross proceeds of the offering will be approximately $10 million before deducting fees and other estimated offering expenses.

Key Points: 
  • The gross proceeds of the offering will be approximately $10 million before deducting fees and other estimated offering expenses.
  • The closing of the offering is expected to take place on or about April 5, 2024, subject to the satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
  • A final prospectus supplement and accompanying base prospectus relating to the offering will be filed by Matinas BioPharma with the SEC.

Zhibao Technology Inc. Announces Pricing of Initial Public Offering

Retrieved on: 
Tuesday, April 2, 2024
Fintech, Madison Avenue, EF Hutton, Offering, Form, Telephone, Sale, Attention, Security (finance), Prospectus, File

The offering is expected to close on April 3, 2024, subject to customary closing conditions.

Key Points: 
  • The offering is expected to close on April 3, 2024, subject to customary closing conditions.
  • EF Hutton LLC is acting as the sole book-running manager for the Offering.
  • The Offering is being made only by means of a prospectus, forming part of the effective registration statement.
  • In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC's website at www.sec.gov .

Interfield Global Software Inc. Announces Delay in Filing of Annual Filings and Director Resignation

Retrieved on: 
Monday, April 1, 2024
MNP, Policy, News, National instrument, Bank statement, File, MNP LLP, National Policy, Cryptocurrency

As a result, the Company will also be delayed in filing of its Annual Information Form for the year ended December 31, 2023 (the “AIF”).

Key Points: 
  • As a result, the Company will also be delayed in filing of its Annual Information Form for the year ended December 31, 2023 (the “AIF”).
  • The Company has made all efforts and allocated all available resources to the preparation, completion and filing of the Annual Filings.
  • The Company’s auditors have also made significant efforts to complete their audit of the annual financial statements.
  • Upon filing its Annual Filings, the Company will also file its AIF.

Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2023

Retrieved on: 
Monday, April 1, 2024
Combination, Tax, COVID, Growth, Business, Form, Travel, Class, Sub, Business analyst, Adjustment, Investment, Depreciation, File, Mergers and acquisitions, Cryptocurrency

PLAINVIEW, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO) today announced its operating results for the three months and year ended December 31, 2023.

Key Points: 
  • PLAINVIEW, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO) today announced its operating results for the three months and year ended December 31, 2023.
  • I, a Delaware corporation (“Achari”) (NASDAQ: AVHI), and Achari Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Achari (“Merger Sub”).
  • Gross profit for the fourth quarter of 2023 decreased by 4.0% to $14.1 million, compared with a gross profit of $14.6 million for the same quarter of 2022.
  • Selling, general and administrative (SG&A) and R&D expenses for the fourth quarter of 2023 increased by 14.7% to $12.9 million, compared to $11.3 million for the fourth quarter of 2022.

BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, April 1, 2024
Sickle cell disease, Biotechnology, Blue, DSM-IV codes, Patient, History, Class, News, Cancer, Complaint, File, SCD, FDA, BLA, Court, Bluebird bio, Food, Person, Pharmaceutical industry

According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points: 
  • According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Blue you have until May 28, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Movella Files Form 25 to Voluntarily Delist its Securities from The Nasdaq Stock Market LLC

Retrieved on: 
Monday, April 1, 2024
MVLA, Software, Security (finance), OTC, File, Movement

The Company expects that trading will be suspended on April 2, 2024 prior to the market opening and that the delisting will occur ten days after the filing of Form 25.

Key Points: 
  • The Company expects that trading will be suspended on April 2, 2024 prior to the market opening and that the delisting will occur ten days after the filing of Form 25.
  • Following the delisting, any trading in the Securities would only occur in privately negotiated sales and potentially on an over‐the‐counter market.
  • The Company expects to have its Securities quoted on a market operated by OTC Markets Group Inc. (the “OTC”) around or after April 12th so that a trading market may continue to exist for the Securities.
  • There is no assurance, however, that a broker will continue to make a market in the Securities or that trading thereof will continue on an OTC market or otherwise.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, April 1, 2024
Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Prospectus, Complaint, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points: 
  • On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
  • Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • As of the time the Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX

Retrieved on: 
Sunday, March 31, 2024
Psoriasis, Register, Form, District court, Defendant, News, Ext, LLP, IPO, Security (finance), Inflammation, Plaque, Prospectus, Complaint, File, Pomerantz, Action Replay, Court, Person

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against bluebird bio, Inc. (BLUE)

Retrieved on: 
Saturday, March 30, 2024
Sickle cell disease, Biotechnology, Bluebird, Clinical, SAN, DSM-IV codes, Patient, History, News, LLP, Cancer, Commercial, Complaint, BLUE, File, SCD, FDA, BLA, Bluebird bio, Food, Person, Pharmaceutical industry

SAN DIEGO, March 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023.

Key Points: 
  • SAN DIEGO, March 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023.
  • Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

BLUE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Bluebird bio Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 29, 2024
Sickle cell disease, Biotechnology, Telephone, Blue, District court, DSM-IV codes, Defendant, Patient, History, News, Cancer, False, Complaint, P.C, Elivaldogene autotemcel, SCD, File, FDA, BLA, Court, Food, Person

Investors have until May 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 27, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • According to the complaint, the Company’s announcement provided investors with false and misleading information in order to bolster investor expectations and share prices.